Oncology Analytics builds evidence-based, real-world data and analytics solutions and a technology-enabled utilization management platform purpose-built for oncology. Its prior authorization platform is used by physicians to support 5 million health plan members across the US and Puerto Rico and covers chemotherapy, radiation, precision and targeted therapies, and supportive care. The company serves health plans, providers, and patients with analytics-driven utilization management and related services. Leadership is led by CEO Rick Dean. Oncology Analytics plans to expand its oncology-focused capabilities and accelerate its real-world data and analytics solutions for health plans while increasing market share of its utilization management technology. Oncology Analytics is a Plantation, FL-based technology-enabled service company that provides health plans, providers and patients with an evidence-based, analytics-focused approach to utilization management purpose-built for oncology. Led by CEO Rick Dean, the company offers an e-Prior Authorization platform that is updated daily to reflect more than 6,000 oncology treatment protocols across all cancer types and stages. Its platform is used by physicians to support over 3.5 million health plan members in the U.S. and Puerto Rico. Oncology Analytics closed a $21M Series B financing to expand its oncology benefits management capabilities. The company intends to use the funds to accelerate strategic investments in data analytics, data science and innovative digital health technologies. As part of the announcement, Annie Lamont and Ezekiel J. 'Zeke' Emanuel joined Oncology Analytics' board of directors. Oncology Analytics is a URAC-accredited provider of web-based oncology management and chemotherapy decision support services. Its proprietary clinical decision support system, backed by an in-house team of board-certified hematologists and oncologists and a library of over 2,800 treatment protocols, delivers real-time expertise to treating physicians. The company focuses on ensuring treatments are efficacious, less toxic, and cost-effective, reducing unnecessary costs for payers and providers. OA has experienced rapid growth and nationwide success in chemotherapy decision support and is expanding to address all aspects of cancer care from screening and diagnosis through genetic testing, therapy optimization and end-of-life care. The company recently secured a $7.5 million investment to broaden product development, acquire strategic relationships, and hire new staff to accelerate growth. Dr. Marc Fishman founded OA in 2009 and leads the company as CEO.

Total raised

$57M

Funding rounds

3

Latest round

Series C

Latest activity

May 2020